CDKN2A and melanoma: Approximately 20–30% of melanomas show loss of p16INK4a due to promoter hypermethylation [23,27], and although p14ARF gene methylation is less studied, one study found that the p14ARF promoter was hypermethylated in 34/60 (57%) melanoma metastases.